Main Page Article Search E-Lerts™ Newsletter: Current E-Lerts™ Newsletter Archives E-Lerts™ Newsletter Recipes Archives Defeat Diabetes® E-Lerts™ Newsletter Subscribe Defeat Diabetes ® News by Daniel H. Rasolt Books You Can Use™ Subscribe to Defeat Diabetes Foundation Mailings
About Diabetes Body Care Children Complications Defeat Diabetes Foundation Drugs Elderly E-Lerts™ Governments & Organizations Health & Fitness Insulin MADDCAP™ Mr. Diabetes® Nutrition Obesity Other Diseases Pregnancy Research Risks Self-Management    » A1c    » Alcohol    » Alternative Medicine    » Beverages    » Care    » Cats    » Children    » Complications    » Control    » Dental    » Diet    » Dogs    » Drugs    » Education    » Elderly    » Environment    » Exercise    » Eye Care    » Family    » Food    » Foot Care    » Hearing    » Insulin    » Lifestyle    » Long-term    » Managing    » Men    » Minorities    » Monitor    » Nutrition    » Obesity    » Other Diseases    » Pets    » Pre-Diabetes    » Pregnancy    » Prevention    » Risks    » Salt    » Self-Management    » Sleep    » Smoking    » Spices    » Stress    » Sugar    » Supplements    » Technology    » Warning Signs    » Women Supplements Type 1 Warning Signs

 

 

 

     

Self-Management » Drugs

Search our News Articles Archives for diabetes and health news. Search by word or phrase.  The latest article will appear first.

Search For:  

Search in all categories / subcategories
Search in current category / subcategory

More Evidence of Increased Fractures With Thiazolidinediones Posted: Wednesday, June 25, 2008

Further evidence that long-term use of the thiazolidinediones rosiglitazone and pioglitazone may increase risk of fractures (particularly of the hip and wrist) has come from a new case-control study.

No Efficacy or Safety Sacrifice with Weekly Exenatide (Byetta LAR) Posted: Friday, June 20, 2008

A long-acting version of the injectable diabetes drug exenatide (Byetta) showed efficacy advantages and safety comparable to the standard formulation given twice a day, researchers said.

HEART2D Study Shows No Cardiovascular Benefit by Targeting Postprandial Glucose Levels Posted: Friday, June 20, 2008

A study examining the effects of hyperglycemia on type 2 diabetes patients after acute myocardial infarction (AMI), the Hyperglycemia and Its Effect After Acute Myocardial Infarction on Cardiovascular Outcomes in Patients With Type 2 Diabetes (HEART2D) study, found no cardiovascular benefits from tightly controlling postprandial variations in blood glucose.

Further Evidence Supports Vitamin-D-Deficiency Link to CHD Posted: Friday, June 20, 2008

Further evidence that vitamin-D deficiency may increase the risk of heart disease has come from a new case-control study.

Investigational DPP-4 Inhibitor Effective as Add-On and Stand-Alone Posted: Friday, June 20, 2008

Alogliptin, an investigational once-daily oral drug for type 2 diabetes, showed good efficacy and safety both as monotherapy and together with standard agents, researchers in five phase III trials stated at ADA Scientific Sessions.

Diabetic Ulcer Gel Gets Black Box Warning Posted: Friday, June 20, 2008

A black box warning has been added to the safety labeling for becaplermin gel (Regranex, Johnson & Johnson) to warn of the increased risk for cancer mortality in patients who use 3 or more tubes of the product, the US Food and Drug Administration (FDA) announced on Friday.

Diabetes Prevention Hopes Revived for Thiazolidinedione Posted: Friday, June 20, 2008

Pioglitazone (Actos) may prevent or delay progression to diabetes for patients with pre-diabetes by 81%, researchers found.

Medicine Might Help Prevent Diabetic Retinopathy Posted: Friday, June 13, 2008

Diabetics who take the drug rosiglitazone may significantly decrease the chance of visual impairments and blindness. This drug appears to fend off the common and troubling condition known as diabetic retinopathy.

Monotherapy BYETTA(R) (Exenatide) As Stand Alone Therapy Posted: Wednesday, June 11, 2008

Submitted to FDA for Stand-Alone Therapy in Q1 2008, studies show that exenatide can lower A1c 0.7 to 0.9 points as a monotherapy.

Type 2 Patients Taking Exenatide Once Weekly Improved Glycemic Control, Weight, and Lipid Profiles Posted: Wednesday, June 11, 2008

Amylin, Eli Lilly and Alkermes announced results from the DURATION-1 trial, a 30-week study that compared the efficacy of exenatide once weekly, a long-acting release formulation of exenatide, to BYETTA(R) (exenatide) injection.

 

 

 

 

 

 Costa Rica Travel Corp. will donate a portion of the proceeds to and is a sponsor of Defeat Diabetes Foundation.